EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

French prospective cohort study of predictors of fruquintinib efficacy in real-world metastatic colorectal cancer (PRODIGE 108 - COHORTE 2320 - COFRUQ)

Marie Muller, Thomas Aparicio, Romain Cohen, Claire Gallois, Alexis Delattre, Elena Paillaud, Thibault Mazard, Manon Pelkowski, Jean-Marc Phelip, Violaine Randrian, Pierre Laurent-Puig, Lauriane Goldwirt und 7 weitere

Digestive and Liver Disease · 2026-10

DOI: 10.1016/j.dld.2026.10.010 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Digestive and Liver Disease, 2026-10. Verfasst von Marie Muller und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of Lorraine, Department of Hepato-Gastroenterology and Digestive Oncology, Nancy University Hospital, Nancy, France. Electronic address: m…. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. In unresectable metastatic (m)CRC, systemic therapy is the standard of care, and maintaining anti-angiogenic pressure remains important in the chemorefractory setting, as shown in 2nd and 3rd line treatment. Fruquintinib, a selective tyrosine kinase inhibitor of VEGF receptors 1, 2, and 3, recently demonstrated a 2.6-month overall survival benefit versus placebo in advanced mCRC and is now a new option for heavily pre-treated patients. However, real-world data on fruquintinib use and predictors of its efficacy remain limited. DESIGN: PRODIGE108-COHORTE2320 - COFRUQ (NCT07124858) is a French multicentre prospective observational cohort primarily designed to identify clinical and biological factors associated with fruquintinib efficacy under real-world conditions. The primary endpoint is investigator-assessed overall survival. Main secondary objectives include progression-free survival, objective response rate, disease control rate, safety, and quality of life. Eligible patients are ≥18 years old with histologically confirmed mCRC receiving fruquintinib within its EMA indication. Biological studies (tumour and blood collection) will identify prognostic and predictive biomarkers, alongside pharmacokinetic analyses. The cohort aims to enrol 300 patients over 3 years and has been open for enrolment in France since March 2026.

Schlagwörter

Stichwörter der Autor:innen

FruquintinibMetastatic colorectal cancerProspective cohortReal world dataSystemic therapy

Autor:innen und Institutionen

  • University of Lorraine, Department of Hepato-Gastroenterology and Digestive Oncology, Nancy University Hospital, Nancy, France. Electronic address: m.muller7@chru-nancy.fr.
  • Department of Gastroenterology, Université Paris Cité, Saint Louis Hospital, APHP, Paris, France.
  • Sorbonne Université and Department of Medical Oncology, Saint-Antoine Hospital, Paris, France.
  • Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France.
  • Fédération Francophone de Cancérologie Digestive, Université Bourgogne Europe, INSERM CTM 1231 EPICAD, Dijon, France.
  • Department of Geriatric Medicine, Hôpital Européen Georges Pompidou, Paris, France.

Zitieren

APA

Muller, M., Aparicio, T., Cohen, R., Gallois, C., Delattre, A., Paillaud, E., Mazard, T., Pelkowski, M., Phelip, J. M., Randrian, V., Laurent-Puig, P., Goldwirt, L., Perret, A., Bachet, J. B., Akouz, F. K., Couteau, C., Hautefeuille, V., Lepage, C., & Tougeron, D. (2026). French prospective cohort study of predictors of fruquintinib efficacy in real-world metastatic colorectal cancer (PRODIGE 108 - COHORTE 2320 - COFRUQ). Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.10.010

Vancouver

Muller M, Aparicio T, Cohen R, Gallois C, Delattre A, Paillaud E, et al. French prospective cohort study of predictors of fruquintinib efficacy in real-world metastatic colorectal cancer (PRODIGE 108 - COHORTE 2320 - COFRUQ). Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.10.010

BibTeX
@article{Muller2026,
  author = {Muller, Marie and Aparicio, Thomas and Cohen, Romain and Gallois, Claire and Delattre, Alexis and Paillaud, Elena and Mazard, Thibault and Pelkowski, Manon and Phelip, Jean-Marc and Randrian, Violaine and Laurent-Puig, Pierre and Goldwirt, Lauriane and Perret, Audrey and Bachet, Jean-Baptiste and Akouz, Faiza Khemissa and Couteau, Corinne and Hautefeuille, Vincent and Lepage, Côme and Tougeron, David},
  title = {French prospective cohort study of predictors of fruquintinib efficacy in real-world metastatic colorectal cancer (PRODIGE 108 - COHORTE 2320 - COFRUQ)},
  journal = {Digestive and Liver Disease},
  year = {2026},
  doi = {10.1016/j.dld.2026.10.010}
}
Kostenlos starten →